Benzodiazepines can affect blood sugar, though the direction and size of the effect depend heavily on the dose, the specific drug, and whether a person already has diabetes. In controlled human trials, single doses of certain benzodiazepines reduced insulin sensitivity and slowed glucose clearance, while animal studies show dose-dependent rises in blood glucose. Paradoxically, one clinical trial found that alprazolam actually improved long-term glucose control in people with diabetes. The picture gets stranger in overdose settings, where hypoglycemia becomes a real concern. For most people taking a standard prescription, the blood sugar shifts are modest enough that population-level studies find no link to developing diabetes, but the topic holds genuine surprises worth understanding.
Why GABA Receptors Matter Beyond the Brain
Benzodiazepines work by amplifying the activity of GABA, a chemical messenger that quiets nerve cells. Most people think of this as a brain effect, and it is: that calming action is what relieves anxiety and induces sleep. But GABA receptors are not confined to the brain. The insulin-producing clusters of cells in the pancreas, known as islets, actually produce and release GABA themselves. Within those islets, GABA helps regulate hormone secretion and shapes how immune cells interact with pancreatic tissue.1PubMed Central. GABA signalling in human pancreatic islets When a benzodiazepine enters the bloodstream and enhances GABA signaling everywhere, the pancreas is not exempt.
There is also an indirect route through stress hormones. Cortisol, which the body releases during stress, raises blood sugar by encouraging the liver to release stored glucose and by making cells less responsive to insulin. Benzodiazepines suppress cortisol production in a dose-dependent way, at least in the short term. A study using oxazepam found that a single dose lowered cortisol levels for two to three hours, an effect that appeared to work by dampening the brain’s signal to release the hormone that kicks off the cortisol cascade.2PubMed. Benzodiazepine suppression of cortisol secretion: a measure of anxiolytic activity? Lower cortisol should, in theory, nudge blood sugar downward. So the drug simultaneously acts on the pancreas (via GABA) and on stress hormones (via cortisol suppression), and those two pathways can push glucose in different directions depending on the circumstances.
What a Single Dose Does to Insulin and Glucose
The clearest controlled data on short-term effects comes from a double-blind, placebo-controlled crossover trial that gave healthy volunteers single doses of clonazepam or alprazolam and then measured how their bodies handled a glucose load. The results were dose-dependent. As clonazepam blood levels rose, the body’s immediate insulin response declined. In volunteers who reached the higher end of therapeutic drug concentrations, insulin sensitivity dropped to roughly half of what it was under placebo, and the overall rate at which the body cleared glucose from the bloodstream fell by a similar proportion.3PubMed Central. Assessment of single-dose benzodiazepines on insulin secretion, insulin sensitivity and glucose effectiveness in healthy volunteers: a double-blind, placebo-controlled, randomized cross-over trial In practical terms, the drug made these healthy people temporarily worse at processing sugar.
Animal data paints a consistent picture. A study in rats found that both diazepam and midazolam raised blood glucose levels in a dose-dependent manner, with the effect attributed to impaired glucose uptake by peripheral tissues rather than a spike in glucose production by the liver.4Critical Care. Benzodiazepines induce hyperglycemia in rats by affecting peripheral disposal of glucose The researchers flagged this as particularly relevant for critically ill patients, who are often given intravenous benzodiazepines for sedation in hospital settings where blood sugar control already matters a great deal.
It is worth noting the scale here. In the human trial, the average effect across all participants was not dramatic enough to reach statistical significance; it only became clearly significant in those with higher drug concentrations. A person taking a standard low-dose benzodiazepine for occasional anxiety is unlikely to see a clinically meaningful glucose spike. The concern ramps up at higher doses, with repeated use, or in someone whose glucose regulation is already impaired.
An Unexpected Benefit for Some People with Diabetes
One of the more surprising findings in this area comes from a double-blind, placebo-controlled trial that gave alprazolam to people with diabetes who had a history of poor blood sugar control. After a short course of treatment, those on alprazolam saw their glycated hemoglobin (a measure of average blood sugar over several months) drop by about 1.1 percentage points compared with only 0.3 points in the placebo group.5Diabetes Care. Effects of alprazolam on glucose regulation in diabetes: Results of a double-blind, placebo-controlled trial A drop of that size is meaningful, roughly comparable to what some oral diabetes medications achieve. The researchers noted that the improvement was not simply a byproduct of reduced anxiety: even after accounting for changes in anxiety symptoms, the glucose benefit remained.
How does that square with the evidence that benzodiazepines worsen insulin sensitivity in healthy people? Several things could explain the disconnect. People with poorly controlled diabetes often have elevated stress hormones, and the cortisol-lowering effect of benzodiazepines may carry more weight in that context. Chronic anxiety and poor sleep, both of which benzodiazepines address, independently worsen blood sugar. And the metabolic starting point matters: a drug that slightly dampens insulin response in a healthy person may, by calming stress pathways, produce a net positive in someone whose glucose is chronically elevated by stress.
This does not mean benzodiazepines are a diabetes treatment. A separate study in patients with panic disorder found that adding alprazolam to the antidepressant sertraline was associated with significant increases in fasting blood sugar, post-meal blood sugar, and glycated hemoglobin over three months, while sertraline alone lowered those same markers.6Cyprus Journal of Medical Sciences. Effects of Alprazolam and Clonazepam on Blood Sugar in Patients with Panic Disorder The practical takeaway is that benzodiazepines do not have a single predictable direction of effect on glucose. The population, the co-prescribed medications, and the underlying metabolic state all shift the needle.
Does Long-Term Use Raise the Risk of Developing Diabetes?
Given the short-term metabolic effects, you might expect chronic benzodiazepine users to show higher rates of type 2 diabetes. The epidemiological evidence does not support that worry. A large study followed over 125,000 people with insomnia for a median of more than 14 years and compared diabetes incidence between benzodiazepine users and non-users. While a slightly higher percentage of users developed diabetes (about 7.8% versus 5.5%), that difference disappeared after adjusting for other factors like age, weight, and comorbidities. The study found no independent association between benzodiazepine use and type 2 diabetes risk.7PubMed. The Use of Benzodiazepines and Risk of Incident Type 2 Diabetes in the General Population with Insomnia
A cross-sectional analysis of U.S. national health survey data reached a similar conclusion. Among nearly 4,700 participants, those who had used benzodiazepine sleep aids for three months or longer showed no statistically significant increase in prediabetes rates, with adjusted odds ratios hovering close to 1.0 across several different thresholds of elevated glycated hemoglobin.8PubMed Central. Association of long-term benzodiazepine hypnotic use and prediabetes in US population: A cross-sectional analysis of national health and nutrition examination survey data This study was limited by a very small number of benzodiazepine users in the sample, which makes it harder to detect subtle effects. But taken together with the larger insomnia cohort, the message is reassuring: long-term benzodiazepine prescriptions, at typical therapeutic doses, do not appear to meaningfully raise your odds of becoming diabetic.
The caveat is that both studies looked at standard prescribed doses in general populations. They cannot tell us much about what happens in people who take high doses, combine benzodiazepines with other medications that affect glucose, or already sit on the edge of metabolic dysfunction. The absence of a population-level signal does not mean every individual is unaffected.
Overdose and the Risk of Hypoglycemia
The metabolic picture changes dramatically at toxic doses. A study of 300 poisoning patients, of whom about 17% had taken benzodiazepine overdoses, found that hypoglycemia was roughly four times more common in the benzodiazepine-poisoned group than in patients poisoned by other substances. The hypoglycemia rate was about 12% in benzodiazepine cases versus 3% in other poisonings.9PubMed Central. Occurrence of hypoglycemia in patients with benzodiazepines poisoning: A cross-sectional study The risk was concentrated among men, people over 30, those with severely depressed consciousness, and those who arrived at the hospital more than an hour after ingestion.
This finding matters for emergency medicine. A person in a benzodiazepine overdose is deeply sedated and unable to eat, which already predisposes to low blood sugar. But the association held even after accounting for the general effects of poisoning and low consciousness levels, suggesting something pharmacological is happening at very high doses. Whether this reflects massive GABA-mediated insulin release from the pancreas, profound cortisol suppression, or some other mechanism is not fully worked out. For practical purposes, it means that blood glucose monitoring should be part of the standard workup for any suspected benzodiazepine overdose, and clinicians should be prepared to treat low blood sugar alongside the more commonly discussed risks like respiratory depression.
A related concern is that benzodiazepine sedation can mask the symptoms of low blood sugar. The early warning signs of hypoglycemia, such as shakiness, racing heart, and sweating, are driven by adrenaline. Heavy sedation dulls those signals, which could allow blood sugar to drop further before anyone notices. This is especially relevant for people with diabetes who are taking insulin or sulfonylureas and also use benzodiazepines, even at prescribed doses. If you fall asleep after a benzodiazepine and miss a meal, the usual alarm system that would wake you with hypoglycemia symptoms may not fire as loudly.
Counterfeit Pills and an Unexpected Danger
There is a blood-sugar danger from benzodiazepines that has nothing to do with the drugs themselves. Counterfeit pills sold as “street Valium” or similar products have repeatedly been found to contain adulterants, including drugs from entirely different classes. One documented case involved pills that, in addition to various illicit substances, contained glyburide, a sulfonylurea medication used to treat diabetes. Sulfonylureas work by forcing the pancreas to release more insulin, and they can cause dangerous hypoglycemia in anyone without diabetes who swallows them.10PubMed Central. Hypoglycemia After Ingestion of “Street Valium” Containing Glyburide, Alcohol, and Cocaine A person buying what they believe is diazepam from an unregulated source could unknowingly take a potent blood-sugar-lowering drug and develop severe hypoglycemia that neither they nor emergency responders would initially attribute to a “benzodiazepine.”
This is not a theoretical concern. Emergency departments have documented patients presenting with life-threatening low blood sugar after taking pills purchased as benzodiazepines. The lesson here is narrow but important: illicitly sourced benzodiazepines carry metabolic risks that prescribed, pharmaceutical-grade versions do not, because you cannot know what else is in the tablet.
Practical Considerations for Different Groups
The evidence collectively suggests different things for different people. If you are generally healthy and take an occasional low-dose benzodiazepine for anxiety or a medical procedure, the blood sugar effects are unlikely to be clinically relevant. The modest, short-lived changes seen in the human trial were only significant at the higher end of drug concentrations. Your body’s normal regulatory machinery can handle a small, temporary dip in insulin sensitivity.
If you have type 2 diabetes and are prescribed a benzodiazepine, the picture is more nuanced. On one hand, the cortisol suppression and anxiety reduction could conceivably help your glucose control, consistent with the alprazolam trial that found improved hemoglobin A1c. On the other hand, the study combining alprazolam with sertraline in panic disorder patients found worsened blood sugar markers, suggesting the combination with certain other medications may flip the effect. The safest approach is to monitor your blood sugar a bit more closely when starting or stopping a benzodiazepine and to let your doctor know about any noticeable shifts.
If you take insulin or a sulfonylurea, the sedation issue deserves specific attention. Benzodiazepines can make you sleepy enough to skip meals or sleep through hypoglycemia warning signs. This does not mean you cannot take them, but it does mean timing matters. Taking a benzodiazepine on an empty stomach right before bed, especially after a dose of fast-acting insulin, is a combination that warrants extra caution, perhaps a bedside glucose check or a snack before sleep.
Older adults face compounded risks. They metabolize benzodiazepines more slowly, meaning higher drug levels persist for longer and the window for metabolic effects widens. They are also more likely to be on diabetes medications, to have impaired glucose regulation to begin with, and to experience serious consequences from a hypoglycemic episode like a fall. None of this is an absolute prohibition, but it adds weight to the general geriatric guidance that benzodiazepines should be used at the lowest effective dose for the shortest practical duration.
Intensive Care and Hospital Settings
One setting where benzodiazepine-related blood sugar effects become genuinely important is the intensive care unit. Critically ill patients are frequently sedated with intravenous midazolam, sometimes for days. These patients are already prone to stress-induced hyperglycemia, and tight glucose management in the ICU has been a subject of intense clinical interest for decades. The animal data showing dose-dependent hyperglycemia with midazolam suggests that benzodiazepine sedation could be an underappreciated contributor to the high blood sugar levels commonly seen in these patients.4Critical Care. Benzodiazepines induce hyperglycemia in rats by affecting peripheral disposal of glucose
This has practical implications for sedation choices. Many ICUs have already moved toward non-benzodiazepine sedatives like propofol or dexmedetomidine for other reasons, including lower rates of delirium. If benzodiazepine sedation also worsens glucose control, that is one more reason supporting the shift. For the individual patient, it means that unexplained hyperglycemia during a prolonged benzodiazepine infusion should at least prompt consideration of the sedative as a contributing factor, not just the stress response or the dextrose in the IV bag.
Research in this area remains thin. Most of the controlled human data comes from single-dose studies in healthy volunteers, and the overdose data from emergency departments captures an extreme end of the spectrum. The space between a single therapeutic dose and a toxic overdose, which is where chronic prescribed use and multi-day ICU infusions actually live, is poorly mapped. It is one of those corners of pharmacology where clinicians rely on a patchwork of animal studies, small trials, and clinical intuition rather than the kind of large, definitive evidence base that exists for, say, the blood sugar effects of corticosteroids.